How to Finance an Independent Pharmacy Acquisition with an SBA Loan
SBA 7(a) loans are the most common financing vehicle for acquiring independent pharmacies in the $1M–$5M revenue range. Here is what pharmacy buyers need to know about eligibility, deal structure, and navigating the regulatory complexity that makes pharmacy acquisitions unique.
Find SBA-Eligible Pharmacy BusinessesSBA Overview for Pharmacy Acquisitions
Independent pharmacy acquisitions are well-suited for SBA 7(a) financing because they typically involve established businesses with recurring prescription revenue, identifiable cash flow, and tangible assets including inventory and prescription files that lenders can underwrite. Most independent pharmacies in the lower middle market generate $1M–$5M in annual revenue with EBITDA margins of 8–15%, putting them squarely in the range where SBA financing is both available and practical. The SBA 7(a) program allows buyers to finance up to $5 million with as little as 10% down, making it possible for a licensed pharmacist or operator to acquire a community pharmacy without needing to bring institutional capital to the table. However, pharmacy acquisitions carry unique underwriting considerations that general SBA lenders are not always equipped to handle — including how lenders value a prescription file, how they treat PBM reimbursement risk, and how DEA change-of-ownership requirements affect deal timing and closing conditions. Working with an SBA lender experienced in healthcare services and specifically in pharmacy transactions is critical to getting a deal structured and funded correctly.
Down payment: Most SBA lenders require a minimum 10% equity injection for pharmacy acquisitions where the business has strong financials and the purchase price is well-supported by cash flow. However, buyers should expect lenders to require 15–20% equity when a significant portion of the purchase price is allocated to goodwill and prescription file value — intangible assets that carry higher risk in lender underwriting. In practice, the most competitive pharmacy acquisition deals are structured with a combination of buyer equity of 10–15%, seller carry of 10–20% on a subordinated note (which the SBA allows to count toward the equity injection under certain conditions), and SBA 7(a) financing covering the remaining 65–80% of the deal. Buyers should also reserve separate working capital for inventory at cost, which is typically priced outside the purchase agreement and paid at closing, and for the first 90–120 days of operating expenses during the transition period while payer credentialing and patient file transfers are completed.
SBA Loan Options
SBA 7(a) Standard Loan
10-year repayment for business acquisitions; interest rates typically Prime plus 2.25–2.75%, currently ranging from approximately 10–11.5% depending on lender and deal structure
$5,000,000
Best for: Acquiring an independent retail or compounding pharmacy with an established prescription file, patient base, and documented cash flow; ideal for pharmacist-buyers seeking to finance the full acquisition including goodwill, equipment, and working capital in a single loan structure
SBA 7(a) Small Loan
10-year repayment for acquisitions; streamlined underwriting with faster approval timelines compared to standard 7(a) loans
$500,000
Best for: Smaller independent pharmacy acquisitions or add-on purchases such as acquiring a prescription file from a closing pharmacy or a micro-location with limited hard assets; best when total deal consideration falls below $500,000
SBA 504 Loan
10- or 20-year fixed-rate debenture for the SBA portion; primarily used for fixed asset financing
$5,500,000 combined (SBA debenture up to $5M plus bank portion)
Best for: Pharmacy acquisitions where the buyer is also purchasing the real estate or making significant leasehold improvements to an owned facility; less commonly used for pure business acquisitions without a real property component
Eligibility Requirements
- The buyer must be a U.S. citizen or lawful permanent resident and must plan to actively manage or operate the acquired pharmacy, which for most lenders means holding or obtaining a pharmacist license or partnering with a licensed pharmacist in a management capacity
- The pharmacy being acquired must be a for-profit business operating in the United States with a demonstrable history of revenue and cash flow, typically evidenced by three years of tax returns and monthly prescription volume reports by payer
- The total deal size, including the purchase price, inventory at cost, and working capital, must fall within SBA loan limits, with a maximum SBA 7(a) loan amount of $5 million per borrower
- The buyer must inject a minimum of 10% equity into the transaction, though lenders may require 15–20% equity when the deal involves significant goodwill relative to hard assets, which is common when a large portion of the purchase price is attributed to the prescription file
- The acquired business must pass SBA affiliation and size standards, confirming that the pharmacy qualifies as a small business — for pharmacies, this is generally defined by revenue or employee count thresholds set by the SBA under NAICS code 446110
- The buyer must demonstrate creditworthiness including a personal credit score typically above 680, no recent bankruptcies or significant derogatory credit history, and sufficient personal liquidity to cover the required equity injection and post-close working capital needs
Step-by-Step Process
Identify a Target Pharmacy and Conduct Preliminary Screening
Source acquisition targets through pharmacy-specialized brokers, state pharmacy association networks, or direct outreach to owner-operators approaching retirement. Conduct preliminary screening by reviewing the pharmacy's trailing 12 and 24 months of revenue, active patient count, 30-day refill rates, payer mix, and DEA and state board compliance status. Confirm that the pharmacy's EBITDA supports a purchase price in the range where SBA financing is viable, typically 3x–5.5x adjusted EBITDA for independent pharmacies in the lower middle market.
Engage an SBA Lender with Healthcare and Pharmacy Acquisition Experience
Not all SBA lenders are equipped to underwrite pharmacy acquisitions. Identify lenders with a track record in healthcare services M&A who understand how to value prescription files, analyze PBM contract reimbursement risk, and account for DIR fee exposure in their cash flow analysis. Submit a loan inquiry package including your personal financial statement, business plan, and the target pharmacy's three years of tax returns, P&L statements, and prescription volume reports. Obtain a preliminary term sheet before signing a purchase agreement.
Execute a Letter of Intent and Engage Pharmacy-Specialized Advisors
Draft and negotiate a non-binding letter of intent covering the purchase price, deal structure including allocation between prescription file, inventory, equipment, and goodwill, any seller carry provisions, exclusivity period, and key closing conditions. Engage a pharmacy-specialized M&A attorney and a CPA with healthcare transaction experience to support due diligence, SBA loan documentation, and the regulatory transfer process. Do not use generalist advisors for pharmacy acquisitions given the complexity of DEA, state board, and PBM contract transfer requirements.
Complete Due Diligence on Financials, Compliance, and Payer Contracts
Conduct full due diligence covering the pharmacy's adjusted EBITDA with owner add-backs, prescription file analysis including active patient count and refill rate trends, PBM contract terms and DIR fee exposure, DEA registration status and change-of-ownership requirements, state pharmacy board license transferability, staff credentials and retention risk, inventory valuation, and accounts receivable aging by payer. Flag any compliance issues, payer concentration risk, or declining volume trends early, as these will affect lender underwriting and deal valuation.
Finalize SBA Loan Application and Submit to Lender
Work with your SBA lender to complete the full loan application package, including the executed purchase agreement, business valuation, personal financial statements, three years of business tax returns, a business plan with pharmacy-specific financial projections, and documentation of the equity injection source. The lender will order an independent business appraisal. Expect the lender to scrutinize the prescription file valuation methodology, PBM contract stability, and the buyer's plan for retaining key staff and patients post-transition.
Obtain DEA Change-of-Ownership Approval and State Board Clearance
Simultaneously with the SBA loan process, the buyer must apply for a new DEA registration under the acquiring entity. The DEA does not transfer registrations — the buyer must obtain a new registration and coordinate with the seller on a precise closing date, as the seller's DEA registration remains active until the buyer's is issued. The buyer must also apply for a new state pharmacy board license or permit for the acquiring entity. Both processes can take 60–120 days and must be coordinated carefully to avoid any gap in the pharmacy's ability to legally dispense controlled substances.
Close the Transaction and Execute Payer Credentialing
At closing, finalize the asset purchase agreement, transfer the prescription file, conduct a physical inventory count with the seller for separate pricing at cost, and execute all lease assignments or new lease agreements. Immediately initiate credentialing applications with Medicare Part D, Medicaid managed care organizations, and commercial PBM networks under the new ownership entity. Payer credentialing can take 30–90 days, during which the pharmacy may need to operate under the seller's provider numbers under a transitional services arrangement — confirm this is permissible with each payer and document it properly.
Common Mistakes
- ✗Underestimating the time required for DEA new registration and state board licensing, which routinely causes closing delays of 30–60 days beyond the originally scheduled date and can create financing complications if the SBA commitment letter expires
- ✗Failing to review PBM contracts for change-of-ownership provisions before signing a purchase agreement, which can result in the buyer discovering post-signing that a key PBM network requires re-credentialing or may terminate the contract entirely upon a change of ownership
- ✗Accepting the seller's stated EBITDA without performing a thorough add-back and recast analysis, particularly around owner compensation, personal expenses run through the business, and DIR fees that may not be fully reflected in the trailing income statements
- ✗Using a generalist SBA lender without healthcare acquisition experience who undervalues the prescription file, misunderstands PBM reimbursement dynamics, or declines the loan due to the high proportion of intangible assets — all of which can be avoided by selecting a pharmacy-experienced lender from the outset
- ✗Not negotiating a seller carry or earnout tied to patient file retention, which leaves the buyer fully exposed to the risk that a meaningful portion of the patient base does not transfer to the new owner — a risk that a well-structured earnout or subordinated seller note aligns incentives to mitigate
Lender Tips
- Seek out SBA Preferred Lender Program (PLP) lenders with documented experience in healthcare business acquisitions, specifically pharmacy or medical practice transactions, as they will process your application faster and underwrite pharmacy-specific cash flow more accurately than generalist SBA lenders
- Present a detailed prescription file analysis alongside your financial statements, including active patient count, average prescriptions per patient per year, 30-day refill rates, and payer mix breakdown — lenders who understand pharmacy will weight this data heavily in their underwriting and it demonstrates buyer sophistication
- Proactively address PBM reimbursement risk and DIR fee exposure in your business plan with a concrete strategy, whether that is diversifying into compounding, long-term care contracts, or specialty services, as lenders will flag reimbursement compression as a key risk and want to see that the buyer has a plan
- Structure the seller carry as a full standby note for the first 24 months if possible, as this satisfies SBA equity injection requirements while giving the new owner time to stabilize operations and patient volume before subordinated debt service begins
- Request that the lender order the business appraisal from an appraiser with pharmacy industry experience who understands prescription file valuation methodology, as a generalist appraiser may significantly undervalue or overvalue the intangible assets, creating problems for both financing and deal pricing
Find SBA-Ready Pharmacy Businesses
Pre-screened acquisition targets with verified financials — free to join.
SBA Loan Calculator
Estimate your monthly payment for a Pharmacy acquisition
Standard for acquisitions
Powered by Deal Flow OS
dealflow-os.com · Free M&A tools for every stage of the deal
Frequently Asked Questions
Can I use an SBA loan to buy an independent pharmacy if I am not a licensed pharmacist?
Yes, but with important caveats. The SBA does not require the buyer to hold a pharmacist license, but state pharmacy boards universally require that a licensed pharmacist serve as the pharmacist-in-charge for day-to-day operations. Most SBA lenders will want to see that the buyer either holds a pharmacist license or has a contractual arrangement with a licensed pharmacist-in-charge who will remain with the business post-acquisition. Non-pharmacist buyers such as investors or healthcare operators should factor pharmacist retention risk into their due diligence and ensure their employment agreements with key pharmacists are strong before closing.
How does an SBA lender value a pharmacy's prescription file during underwriting?
SBA lenders underwrite pharmacy acquisitions primarily on cash flow, using the adjusted EBITDA derived from the seller's tax returns and P&L statements. However, the prescription file — representing the active patient base and recurring prescription volume — is the core intangible asset driving business value and is typically supported by an independent business appraisal. Appraisers and lenders look at active patient count, average prescriptions per patient, 30-day refill rates, and payer mix to assess the durability and transferability of cash flow. A pharmacy with high refill rates, diversified payer mix, and low patient churn will support a higher valuation than one dependent on one-time prescriptions or a single PBM network.
What happens to the DEA registration when a pharmacy changes ownership?
DEA registrations are not transferred from seller to buyer. The buyer must apply for a new DEA registration under the new ownership entity before they can legally dispense controlled substances. The seller's DEA registration remains active until the buyer's new registration is issued, at which point the seller must report the change to the DEA. This process typically takes 60–120 days and must be carefully coordinated with the closing date to avoid any period during which the pharmacy cannot dispense Schedule II–V medications. Many pharmacy acquisitions are structured with the DEA approval as a closing condition, meaning the deal does not close until the buyer's DEA registration is in hand.
Can seller financing count toward my SBA down payment requirement?
Yes, under SBA guidelines a seller carry note can count toward the equity injection requirement if it is structured as a full standby note — meaning no principal or interest payments are made to the seller for at least 24 months following closing. This allows the buyer to meet the 10% equity injection requirement with a combination of personal cash and a subordinated seller note without needing to bring additional capital to the table. However, lenders will carefully review the total debt service coverage ratio including the seller note to confirm the business cash flow can support all obligations after the standby period ends.
How long does it typically take to close a pharmacy acquisition using SBA financing?
Most pharmacy acquisitions using SBA 7(a) financing take 90–150 days from a signed letter of intent to closing, though complex transactions can take longer. The primary time drivers are the SBA loan underwriting and approval process (30–60 days with a PLP lender), the DEA new registration process (60–120 days), and state pharmacy board licensing (varies by state, typically 30–90 days). Because the DEA and state board timelines often run longer than the financing timeline, experienced pharmacy buyers initiate regulatory applications immediately upon signing the LOI rather than waiting for loan approval. Payer credentialing under the new ownership entity begins at closing and can take an additional 30–90 days post-close.
What PBM contract issues should I flag with my lender before applying for an SBA loan?
Before applying, review all PBM contracts for change-of-ownership clauses that could trigger termination or re-credentialing requirements upon closing. Lenders will want assurance that the pharmacy's payer contracts — particularly Medicare Part D, Medicaid managed care, and commercial PBM agreements — will remain intact post-acquisition. DIR fee exposure should also be documented and disclosed, as lenders will adjust underwritten EBITDA to account for DIR fees that may not be fully reflected in the seller's reported income. Pharmacies with heavy concentration in a single PBM or preferred network may face additional lender scrutiny or require a larger equity injection to offset the perceived revenue concentration risk.
More Pharmacy Guides
More SBA Loan Guides
Start Finding Pharmacy Deals Today — Free to Join
Find SBA-eligible targets, score seller motivation, and get AI-written outreach in one platform.
Create your free accountNo credit card required